Study of Molecular Mechanisms Involved in the Pathogenesis of Immune-Mediated Inflammatory Diseases, using Psoriasis As a Model
- Authors: Piruzian ES1, Sobolev VV1, Abdeev RM2, Zolotarenko AD1, Nikolaev AA1, Sarkisova MK1, Sautin ME1, Ishkin AA1, Piruzyan A.L2, Ilyina SA2, Korsunskaya IM2, Rahimova OY3, Bruskin SA1
- Affiliations:
- Vavilov Institute of General Genetics, Russian Academy of Sciences
- Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
- Moscow Municipal Hospital № 24, Department of Health
- Issue: Vol 1, No 3 (2009)
- Pages: 125-135
- Section: Articles
- URL: http://actanaturae.ru/2075-8251/article/view/10793
- DOI: https://doi.org/10.32607/20758251-2009-1-3-125-135
- Cite item
Abstract
E S Piruzian
Vavilov Institute of General Genetics, Russian Academy of Sciences
Email: eleopiru@vigg.ru
V V Sobolev
Vavilov Institute of General Genetics, Russian Academy of Sciences
R M Abdeev
Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
A D Zolotarenko
Vavilov Institute of General Genetics, Russian Academy of Sciences
A A Nikolaev
Vavilov Institute of General Genetics, Russian Academy of Sciences
M K Sarkisova
Vavilov Institute of General Genetics, Russian Academy of Sciences
M E Sautin
Vavilov Institute of General Genetics, Russian Academy of Sciences
A A Ishkin
Vavilov Institute of General Genetics, Russian Academy of Sciences
An L Piruzyan
Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
S A Ilyina
Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
I M Korsunskaya
Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
O Y Rahimova
Moscow Municipal Hospital № 24, Department of Health
S A Bruskin
Vavilov Institute of General Genetics, Russian Academy of Sciences
- Lowes M.A., Bowcock A.M., Krueger J.G. Pathogenesis and therapy of psoriasis. // Nature. 2007. V. 445 P. 866–873.
- Bowcock A. M. and Krueger J. G. Getting under the skin: the immunogenetics of psoriasis. // Nat. Rev. Immunol. 2005. V. 5. P. 699–711.
- Kulsky J.K., Kenworthy W., Bellgard M. et al. Gene expression profiling of Japanese psoriatic skin reveals an increased activity in molecular stress and immune response signals // J. Mol. Med. 2005. V. 85. P. 964–975.
- Barker J. N. Genetic aspects of psoriasis. // Clin. Exp. Dermatol. 2001. V. 26. № 4. P.321–5.
- Prinz J. C. Psoriasis vulgaris-a sterile antibacterial skin reaction mediated by crossreactive T cells- An immunological view of the pathophysiology of psoriasis. // Clin. Exp. Dermatol. 2001. V. 26. № 4. P. 326–32.
- Bowcock A. M. and Cookson W. O. The genetics of psoriasis, psoriatic arthritis and atopic dermatitis. // Hum. Mol. Genet. 2004. V. 13. № 1. P. R43–55.
- Asumalahti K., Veal C., Laitinen T. et al. Psoriasis Consortium. Coding haplotype analysis supports HCR as the putative susceptibility gene for psoriasis at the MHC PSORS1 locus. // Hum. Mol. Genet. 2002. V. 11. P. 589–597.
- Sagoo G.S., Cork M.J., Patel R. et al. Genome – wide studies of psoriasis susceptibility loci: a review. // Joural of Dermatological Science. 2004. V. 35. P. 171–179.
- Fun X., Yang S., Huang W. et al. Fine mapping of the psoriasis susceptibility locus PSORS1 support HLA-C as the susceptibility gene in the Han Chinese population. // PLoS Genet. 2008. V. 4. P. 1–10.
- Duffin K.C., Chandran V., Krueger G.G. et al. Genetics of Psoriasis and Psoriatic Arthritis: update and future direction (GRAPPA 2007) // J. Rheumatology. 2008. V. 35. № 7. P. 1449–1453.
- Duvic M., Johnson T.M., Rapini R.P. et al. Acquired immunodeficiency syndrome-associated psoriasis and Reiter’s syndrome. // Arch. Dermatol. 1987. V. 123. P. 1622–1632.
- Swerlick R.A., Cunningham M.W., Hall N.K. Monoclonal antibodies cross-reactive with group A streptococci and normal and psoriatic human skin. // J. Invest. Dermatol. 1986. V. 87. P. 367–371.
- Gold M.H., Holy A. K., Roenigk H. H. Jr. Beta-blocking drugs and psoriasis. A review of cutaneous side effects and retrospective analysis of their effects on psoriasis. // J. Am. Acad. Dermatol. 1988. V. 19. P. 837–841.
- Wolf R., Tamir A., Brenner S. Psoriasis related to angiotensin-converting enzyme inhibitors. // Dermatologica. 1990. V. 181. P. 51–53.
- Baker H. Psoriasis – clinical features. // Br. Med. 1971. V. 3. P. 231–233.
- Lazarus G.S., Gilgor R.S. Psoriasis, polymorphonuclear leukocytes, and lithium carbonate. An important clue. // Arch. Dermatol. 1979. V. 115. P. 1183–1184.
- Asumalahti K. Molecular genetics of psoriasis. // Helsinki university biomedical disseration. № 27. 2003.
- Sonkoly E., Wei T., Janson P.C., Saaf A. et al. MicroRN As: novel regulators involved in the pathogenesis of Psoriasis- // PLoS ONE. 2007. V. 2. № 7. P. 1–8.
- Yao Y., Richman L., Morehouse C. et al. Type I Interferon: Potential Therapeutic Target for Psoriasis- // PLoS One. 2008. V. 3. № 7. e2737. P. 1–14
- Livak K.J., Schmittgen T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. // Methods. 2001. V. 25. № 4. P.402–408.
- Podimov V.K., Gladkich S.P., Mishkin V.S., Piruzyan L.A., N-acetyltransferase polymorphism of patients with lupus erythematosus // “The problems of investigation, study and production of new drugs”., Shwiesa, Kaunas. – 1979, P. 52-53.
- Piruzyan L.A. Metabolic human passport – the basis of new strategy in pharmacology // Vestnik of RAS. 2004. V.74. P. 610-618.
- Piruzyan L.A. On pharmacological metrology // Bull. USSR Academy of Sci., Biol.. 1990. №2. P. 302-303.
- Gudjonsson J.E, Elder J.T. Psoriasis: epidemiology. // Clinics in Dermatology. 2007. V.25. P. 535–546.
- Piruzyan An.L., Abdeev R.M., Sarkhisova M.K. The role of pharmacogenetics and pharmacogenomics in dermatology // Clinical dermatology and venerology. 2005. №3. P. 8-13
- Bowcock A.M. The genetics of psoriasis and autoimmunity. // Annu. Rev. Genomics Hum. Genet. 2005. V. 6. P. 93–122.
- Piruzyan An.L. Doctoral diss. 2005. №3. P.352
- Piruzyan L.A., Goldenkova I.V., Korsunskaya I.M. et al. Scientific approach to standardization of psoriatic patient’s care (scientific review) // The problems of standardization in health care. 2006. №6. P. 7-13.
- Goldenkova-Pavlova I.V., Piruzyan A.L., Abdeev R.M. et. al. Population analysis and determination of the ethnic background are necessary in the study of multifactorial diseases( a study using the Dagestan population as a model) // Genetika. 2006 V.42, №8. P.1137-42.
- Akhmetova V.L., Galimova E.S., Yusunbaev B.B., Khusnutdinova E.K. The analysis of the genes responsible for susceptibility to psoriasis in Bashkortostan and Khakasia republics // Medical genetics. 2009. №8. P. 29-35.
- Bowcock A.M., Shanon W., Du F. et al. Insight into psoriasis and other inflammatory diseases from large scale gene expression studies. // Hum. Mol. Genet. 2001. V. 10. P. 1793–1805.
- Oestreicher J.L., Walters I.B., Kikichi T. et al. Molecular classification of psoriasis disease-associated genes through pharmacogenomic expression profiling. // Pharmacogenomics J. 2001. V. 1. P. 272–287.
- Nomura I., Gao B., Boguniewicz et al. Distinct pattern of gene expression in the skin lesions of atopic dermatitis and psoriasis: a gene microarray analisys. // J. Allegry Clin. Immunol. 2003. V. 112. P. 1195–1202.
- Zhou X., Krueger J.G., Као M-С.J. et al. Novel mechanism of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63, 100-element oligonucleotide array. // Physiol. Genomics. 2003. V. 13. P. 69–78.
- E.S. Piruzian, T.A. Nikolskaya, R.M. Abdeev, S.A. Brouskin, Transcription Factor AP-1 Components As Psoriasis Candidate Genes // Molecular Biology. 2007, Vol. 41, No.6, pp. 1069–1080.
- Sabat R., Philipp S., Hoflich C., et al. Immunopathogenesis of psoriasis. // Exp Dermatol. 2007. V. 16. № 10. P. 779–98.
- Medzhitov R., Preston-Hurlburt P., Janeway C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. // Nature. 1997. V. 388. P.394–397.
- McInturff J.E., Modlin R.L., Kim J. The role of toll-like receptors in the pathogenesis and treatment of dermatological disease. // J. Invest Dermatol. 2005. V. 125. № 1. P. 1–8.
- Hu X., Chen J., Wang Lu et al. Crosstalk among Jak-STAT, Toll-like receptor, and ITAM dependent pathways in macrophage activation. // Journal of Leukocyte Biology. 2007. V. 82. P. 237–243.
- Schnare M., Barton G. M., Holt A. C. et al. // Nat Immunol. 2001. V.2. № 10. P. 947–950.
- Schjetne K.W., Thompson K.M., Nilsen N. et al. Cutting edge: link between innate and adaptive immunity: Toll-like receptor 2 internalizes antigen for presentation to CD4-T cells and could be an efficient vaccine target. // J. Immunol. 2003. V. 171. № 1. P. 32–36.
- Perez-Lorenzo R., Zambrano-Zaragoza J. F., Moo-Castillo K. et al. IgG class antibodies to heat shockinduced streptococcal antigens in psoriatic patients. // Int J. Dermatol. 2003. V. 42. P. 110–115.
- Krueger J.G. The immunologic basis for the treatment of psoriasis with new biologic agents. // J. Am. Acad. Dermatol. 2002. V. 46. № 1. P. 1–23.
- Reiss Y., Proudfoot A.E., Power C.A. et al. CC Chemokine Receptor (CCR )4 and the CCR 10 Ligand Cutaneous T Cell–attracting Chemokine (CT ACK) in Lymphocyte Trafficking to Inflamed Skin. // J. Exp. Med. V. 194. № 10. 2001.
- Lonsdorf А.S., Hwang S.T., Enk A.H.et al. Chemokine Receptors in T-Cell-Mediated Diseases of the Skin // J. Invest. Dermatol. 2009.
- Honey B., Alenius H., Muller A. et al. CC L27–CCR 10 interactions regulate T cellmediated skin inflammation. // Nat. Med. 2002. V. 8. P. 157–65.
- Chandrasekar B., Mummid S., Valente A. et al. The Pro-atherogenic Cytokine Interleukin18 Induces CXCL16 Expression in Rat Aortic Smooth Muscle Cells via MyD88, Interleukin-1 Receptor-associated Kinase, Tumor Necrosis Factor Receptor-associated Factor 6, c-Src, Phosphatidylinositol 3-Kinase, Akt, c-Jun N-terminal Kinase, and Activator Protein-1 Signaling. // The Journal of biological chemistry. 2005. V. 280. № P. 26263–26277.
- Turpaev K.T. 2006. Role of transcription factor AP-1 in integration of intracellular signal pathways. // Mol. Biol. 40, 945–961.
- Gonsky R., Deem R.L., Hughes C.C. et al. Activation of the CD2 pathway in lamina propria T cells up-regulates functionally active AP-1 binding to the IL-2 promoter, resulting in messenger RN A transcription and IL-2 secretion. // J. Immunol. 1998. V.№ 10. P. 4914–22.
- Bantel H., Schmitz M.L., Raible A. et al. Critical role of NF-kappaB and stress-activated protein kinases in steroid unresponsiveness. // FASEB J. 2002. V. 16. № 13. P. 1832–4.
- Chandrasekar B., Mummidi S., Mahimainathan L. et al. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. // J. Biol. Chem. 2006. V. 281. № 22. P. 15099–109.
- Bruskin S. A. PhD Thesis, 2008. P. 120.
- Takeda A., Higuchi D., Takahashi T. et al. Overexpression of serpin squamous cell carcinoma antigens in psoriatic skin. // J. Invest. Dermatol. 2002. V. 118, № 1. P. 147–1454.
- Bruskin S.A., Abdeev R.M., Moshkovskii S.A. et. al. Psoriasis proteomic research as an approach for identification of potential targets for pharmacotherapy // Clinical dermatology and venerology. 2009. №1. P.28-31.
- Schreiber S., Rosenstiel P., Albrecht M. et al. Genetics of Chron disease, an archetypal inflammatory barrier disease. // Nature. 2005. V. 6. P. 376–388.
- Sartor B.R. Mechanisms of Disease: pathogenesis of Crohn’s disease and ulcerative colitis. // Nature Clinical Practice Gastroenterology - Hepatology. 2006. V. 3. P. 390–407.
- Piruzian E.S., Ishkin A.A., Nikol’Skaya T.A., Abdeev R.M., Bruskin S.A. A comparative analysis of the molecular genetic processes in the pathogenesis and Crohn’s disease, 2009, V.46, №1, P. 175-179
- Сhaudhari U., Romano P., Mulcahy L.D. et al. Efficacy safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. // Lancet. 2001. V. 357. P. 1842–1847.
- Baeten D., Kruithof E., Van den Bosch et al. Sisitematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease- // Ann. Rheum. Dis. 2003. V.62. P. 829–834.
- Sfikakis P.P., Iliopopulus A., Elezoglou A. et al. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. // Arthritis Rheum. 2005. V. 52. P. 2513–2518.
- Peramiquel L., Puig L., Dalmau J. et al. Onset of flexural psoriasis during infliximab treatment for Crohn’s disease. // Clin. Exp. Dermatol. 2005. V. 30. № 6. P. 713–714.
- Umeno J., Matsumoto T., Jo Y. et al. Psoriasis during anti-tumor necrosis factor – alpha therapy for Crohn/s desease. // Inflamm. Bowel Dis. 2007. V. 13. P. 18188–1189.
Views
Abstract - 448
PDF (English) - 157
PDF (Russian) - 214
Cited-By

Article Metrics
Metrics powered by PLOS ALM